Efficacy and Safety of Single-Agent Zandelisib Administered By Intermittent Dosing in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Final Results of the Tidal Phase 2 Study

Andrew D. Zelenetz; W Jurczak; V Ribrag; KM Linton; GP Collins; Mark J Bishton; JL Jiménez; B Dholaria; A Mengarelli; TJ Phillips; NP Sungala; HR Chan; G Musuraca; O Sheehy; JY Yan; WM Xu; M Azoulay; PL Zinzani

doi:10.1182/blood-2022-165409

Efficacy and Safety of Single-Agent Zandelisib Administered By Intermittent Dosing in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Final Results of the Tidal Phase 2 Study

Andrew D. Zelenetz, W Jurczak, V Ribrag, KM Linton, GP Collins, Mark J Bishton, JL Jiménez, B Dholaria, A Mengarelli, TJ Phillips, NP Sungala, HR Chan, G Musuraca, O Sheehy, JY Yan, WM Xu, M Azoulay, PL Zinzani

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	3595-3597
Number of pages	3
Journal	Blood
Volume	140
DOIs	https://doi.org/10.1182/blood-2022-165409
Publication status	Published - 15 Nov 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1182/blood-2022-165409

Cite this

Zelenetz, A. D., Jurczak, W., Ribrag, V., Linton, KM., Collins, GP., Bishton, M. J., Jiménez, JL., Dholaria, B., Mengarelli, A., Phillips, TJ., Sungala, NP., Chan, HR., Musuraca, G., Sheehy, O., Yan, JY., Xu, WM., Azoulay, M., & Zinzani, PL. (2022). Efficacy and Safety of Single-Agent Zandelisib Administered By Intermittent Dosing in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Final Results of the Tidal Phase 2 Study. Blood, 140, 3595-3597. https://doi.org/10.1182/blood-2022-165409

@article{fa6f831a429d480c8e72c42f9f488984,

title = "Efficacy and Safety of Single-Agent Zandelisib Administered By Intermittent Dosing in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Final Results of the Tidal Phase 2 Study",

author = "Zelenetz, {Andrew D.} and W Jurczak and V Ribrag and KM Linton and GP Collins and Bishton, {Mark J} and JL Jim{\'e}nez and B Dholaria and A Mengarelli and TJ Phillips and NP Sungala and HR Chan and G Musuraca and O Sheehy and JY Yan and WM Xu and M Azoulay and PL Zinzani",

year = "2022",

month = nov,

day = "15",

doi = "10.1182/blood-2022-165409",

language = "English",

volume = "140",

pages = "3595--3597",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier BV",

}

Zelenetz, AD, Jurczak, W, Ribrag, V, Linton, KM, Collins, GP, Bishton, MJ, Jiménez, JL, Dholaria, B, Mengarelli, A, Phillips, TJ, Sungala, NP, Chan, HR, Musuraca, G, Sheehy, O, Yan, JY, Xu, WM, Azoulay, M & Zinzani, PL 2022, 'Efficacy and Safety of Single-Agent Zandelisib Administered By Intermittent Dosing in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Final Results of the Tidal Phase 2 Study', Blood, vol. 140, pp. 3595-3597. https://doi.org/10.1182/blood-2022-165409

Efficacy and Safety of Single-Agent Zandelisib Administered By Intermittent Dosing in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Final Results of the Tidal Phase 2 Study. / Zelenetz, Andrew D.; Jurczak, W; Ribrag, V et al.
In: Blood, Vol. 140, 15.11.2022, p. 3595-3597.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Efficacy and Safety of Single-Agent Zandelisib Administered By Intermittent Dosing in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

T2 - Final Results of the Tidal Phase 2 Study

AU - Zelenetz, Andrew D.

AU - Jurczak, W

AU - Ribrag, V

AU - Linton, KM

AU - Collins, GP

AU - Bishton, Mark J

AU - Jiménez, JL

AU - Dholaria, B

AU - Mengarelli, A

AU - Phillips, TJ

AU - Sungala, NP

AU - Chan, HR

AU - Musuraca, G

AU - Sheehy, O

AU - Yan, JY

AU - Xu, WM

AU - Azoulay, M

AU - Zinzani, PL

PY - 2022/11/15

Y1 - 2022/11/15

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_starter&SrcAuth=WosAPI&KeyUT=WOS:000893223203281&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1182/blood-2022-165409

DO - 10.1182/blood-2022-165409

M3 - Meeting Abstract

SN - 0006-4971

VL - 140

SP - 3595

EP - 3597

JO - Blood

JF - Blood

ER -

Efficacy and Safety of Single-Agent Zandelisib Administered By Intermittent Dosing in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Final Results of the Tidal Phase 2 Study

UN SDGs

Access to Document

Other files and links

Cite this